301 related articles for article (PubMed ID: 16211235)
1. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.
Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY
Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235
[TBL] [Abstract][Full Text] [Related]
2. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice.
Peirce SK; Chen WY
Oncogene; 2004 Feb; 23(6):1248-55. PubMed ID: 14647416
[TBL] [Abstract][Full Text] [Related]
3. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma.
Manhès C; Kayser C; Bertheau P; Kelder B; Kopchick JJ; Kelly PA; Touraine P; Goffin V
J Endocrinol; 2006 Aug; 190(2):271-85. PubMed ID: 16899561
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation.
Kirma N; Luthra R; Jones J; Liu YG; Nair HB; Mandava U; Tekmal RR
Cancer Res; 2004 Jun; 64(12):4162-70. PubMed ID: 15205327
[TBL] [Abstract][Full Text] [Related]
5. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.
Chen WY; Ramamoorthy P; Chen N; Sticca R; Wagner TE
Clin Cancer Res; 1999 Nov; 5(11):3583-93. PubMed ID: 10589775
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
Crowley MR; Frost A; Chen DT; Baffi MO; Nicola T; Serra R
Differentiation; 2006 Feb; 74(1):40-52. PubMed ID: 16466399
[TBL] [Abstract][Full Text] [Related]
7. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM
Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968
[TBL] [Abstract][Full Text] [Related]
8. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
9. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R.
Beck MT; Peirce SK; Chen WY
Oncogene; 2002 Aug; 21(33):5047-55. PubMed ID: 12140755
[TBL] [Abstract][Full Text] [Related]
10. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth.
Vomachka AJ; Pratt SL; Lockefeer JA; Horseman ND
Oncogene; 2000 Feb; 19(8):1077-84. PubMed ID: 10713693
[TBL] [Abstract][Full Text] [Related]
11. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis.
Witty JP; Lempka T; Coffey RJ; Matrisian LM
Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342
[TBL] [Abstract][Full Text] [Related]
12. A novel design of targeted endocrine and cytokine therapy for breast cancer.
Zhang G; Li W; Holle L; Chen N; Chen WY
Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
[TBL] [Abstract][Full Text] [Related]
13. Targeted production of proprotein convertase PC1 enhances mammary development and tumorigenesis in transgenic mice.
Blanchard A; Iwasiow B; Yarmill A; Fresnosa A; Silha J; Myal Y; Murphy LC; Chrétien M; Seidah N; Shiu RP
Can J Physiol Pharmacol; 2009 Oct; 87(10):831-8. PubMed ID: 20052009
[TBL] [Abstract][Full Text] [Related]
14. A transgenic mouse model for mammary carcinogenesis.
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM
Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874
[TBL] [Abstract][Full Text] [Related]
15. Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.
Blanco-Aparicio C; Pérez-Gallego L; Pequeño B; Leal JF; Renner O; Carnero A
Carcinogenesis; 2007 Mar; 28(3):584-94. PubMed ID: 17050554
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM; Welsh J
Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
[TBL] [Abstract][Full Text] [Related]
17. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene.
Coffey RJ; Meise KS; Matsui Y; Hogan BL; Dempsey PJ; Halter SA
Cancer Res; 1994 Apr; 54(7):1678-83. PubMed ID: 8137281
[TBL] [Abstract][Full Text] [Related]
18. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis.
Weinstein EJ; Leder P
Cancer Res; 2000 Jul; 60(14):3856-61. PubMed ID: 10919660
[TBL] [Abstract][Full Text] [Related]
19. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation.
Brandt R; Eisenbrandt R; Leenders F; Zschiesche W; Binas B; Juergensen C; Theuring F
Oncogene; 2000 Apr; 19(17):2129-37. PubMed ID: 10815804
[TBL] [Abstract][Full Text] [Related]
20. Prolactin controls mammary gland development via direct and indirect mechanisms.
Brisken C; Kaur S; Chavarria TE; Binart N; Sutherland RL; Weinberg RA; Kelly PA; Ormandy CJ
Dev Biol; 1999 Jun; 210(1):96-106. PubMed ID: 10364430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
